Mutations Associated With Myeloid Neoplasms Risk Post-Stem Cell Transplant
Patients with TP53/PPM1D mutations in their stem cell product had an increased risk of myeloid neoplasms in patients with Hodgkin lymphoma undergoing autologous stem cell transplant.